|
Gene: LECT2 |
Gene summary for LECT2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | LECT2 | Gene ID | 3950 |
Gene name | leukocyte cell derived chemotaxin 2 | |
Gene Alias | chm-II | |
Cytomap | 5q31.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | O14960 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3950 | LECT2 | cirrhotic1 | Human | Liver | Cirrhotic | 4.06e-02 | -7.65e-02 | 0.0202 |
3950 | LECT2 | HCC1 | Human | Liver | HCC | 4.39e-02 | 1.03e-01 | 0.5336 |
3950 | LECT2 | S014 | Human | Liver | HCC | 7.00e-16 | 8.71e-01 | 0.2254 |
3950 | LECT2 | S016 | Human | Liver | HCC | 1.52e-09 | 8.95e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LECT2 | SNV | Missense_Mutation | novel | c.259N>T | p.Ile87Phe | p.I87F | O14960 | protein_coding | deleterious(0) | benign(0.29) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
LECT2 | SNV | Missense_Mutation | novel | c.104N>T | p.Thr35Met | p.T35M | O14960 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
LECT2 | SNV | Missense_Mutation | rs753311386 | c.80N>T | p.Gly27Val | p.G27V | O14960 | protein_coding | deleterious(0) | benign(0.439) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LECT2 | SNV | Missense_Mutation | novel | c.122G>A | p.Cys41Tyr | p.C41Y | O14960 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LECT2 | SNV | Missense_Mutation | novel | c.169G>A | p.Asp57Asn | p.D57N | O14960 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
LECT2 | SNV | Missense_Mutation | rs560184070 | c.202N>A | p.Ala68Thr | p.A68T | O14960 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LECT2 | SNV | Missense_Mutation | c.234N>T | p.Glu78Asp | p.E78D | O14960 | protein_coding | deleterious(0.01) | benign(0.206) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
LECT2 | SNV | Missense_Mutation | c.344N>C | p.Lys115Thr | p.K115T | O14960 | protein_coding | tolerated(0.33) | benign(0.025) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
LECT2 | SNV | Missense_Mutation | c.37N>T | p.Ile13Phe | p.I13F | O14960 | protein_coding | tolerated(0.29) | benign(0.082) | TCGA-D1-A160-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LECT2 | SNV | Missense_Mutation | c.173N>G | p.Ile58Ser | p.I58S | O14960 | protein_coding | deleterious(0) | benign(0.209) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |